NewLink Genetics Corp. (NASDAQ:NLNK) fell 3.2% during trading on Wednesday . The stock traded as low as $10.11 and last traded at $10.19, with a volume of 82,043 shares traded. The stock had previously closed at $10.53.

Several research firms have commented on NLNK. Jefferies Group restated a “hold” rating and issued a $10.00 price objective on shares of NewLink Genetics Corp. in a research report on Wednesday, May 11th. SunTrust Banks Inc. lowered NewLink Genetics Corp. from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $59.00 to $12.00 in a research report on Tuesday, May 10th. Stifel Nicolaus lowered their price objective on NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating on the stock in a research report on Tuesday, May 10th. Zacks Investment Research lowered NewLink Genetics Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, August 3rd. Finally, Robert W. Baird restated a “buy” rating on shares of NewLink Genetics Corp. in a research report on Monday, May 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $23.29.

The stock’s 50-day moving average price is $10.98 and its 200 day moving average price is $15.04. The firm’s market cap is $293.17 million.

NewLink Genetics Corp. (NASDAQ:NLNK) last released its quarterly earnings results on Friday, July 29th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($0.77) by $0.35. Equities research analysts expect that NewLink Genetics Corp. will post ($3.06) earnings per share for the current fiscal year.

A number of hedge funds and institutional investors have recently added to or reduced their stakes in NLNK. California State Teachers Retirement System raised its position in NewLink Genetics Corp. by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 38,523 shares of the company’s stock valued at $1,402,000 after buying an additional 636 shares during the period. Dimensional Fund Advisors LP raised its position in NewLink Genetics Corp. by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 48,507 shares of the company’s stock valued at $1,765,000 after buying an additional 300 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. raised its position in NewLink Genetics Corp. by 134.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 54,775 shares of the company’s stock valued at $1,993,000 after buying an additional 31,375 shares during the period.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.